299 related articles for article (PubMed ID: 34538424)
21. Novel targeted therapies for eosinophil-associated diseases and allergy.
Radonjic-Hoesli S; Valent P; Klion AD; Wechsler ME; Simon HU
Annu Rev Pharmacol Toxicol; 2015; 55():633-56. PubMed ID: 25340931
[TBL] [Abstract][Full Text] [Related]
22. Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities.
Lee LY; Hew GSY; Mehta M; Shukla SD; Satija S; Khurana N; Anand K; Dureja H; Singh SK; Mishra V; Singh PK; Gulati M; Prasher P; Aljabali AAA; Tambuwala MM; Thangavelu L; Panneerselvam J; Gupta G; Zacconi FC; Shastri M; Jha NK; Xenaki D; MacLoughlin R; Oliver BG; Chellappan DK; Dua K
Life Sci; 2021 Feb; 267():118973. PubMed ID: 33400932
[TBL] [Abstract][Full Text] [Related]
23. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
[TBL] [Abstract][Full Text] [Related]
24. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
25. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease.
Tai PC; Ackerman SJ; Spry CJ; Dunnette S; Olsen EG; Gleich GJ
Lancet; 1987 Mar; 1(8534):643-7. PubMed ID: 2882081
[TBL] [Abstract][Full Text] [Related]
26. Quality over quantity; eosinophil activation status will deepen the insight into eosinophilic diseases.
Hilvering B; Koenderman L
Respir Med; 2023 Feb; 207():107094. PubMed ID: 36572067
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol 3-Kinase (PI3K) Orchestrates Aspergillus fumigatus-Induced Eosinophil Activation Independently of Canonical Toll-Like Receptor (TLR)/C-Type-Lectin Receptor (CLR) Signaling.
Dietschmann A; Schruefer S; Westermann S; Henkel F; Castiglione K; Willebrand R; Adam J; Ruland J; Lang R; Sheppard DC; Esser-von-Bieren J; Radtke D; Krappmann S; Voehringer D
mBio; 2022 Aug; 13(4):e0123922. PubMed ID: 35695427
[TBL] [Abstract][Full Text] [Related]
28. Living without eosinophils: evidence from mouse and man.
Jackson DJ; Pavord ID
Eur Respir J; 2023 Jan; 61(1):. PubMed ID: 35953100
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of toxicity mediated by neutrophil and eosinophil granule proteins.
Gigon L; Yousefi S; Karaulov A; Simon HU
Allergol Int; 2021 Jan; 70(1):30-38. PubMed ID: 33277190
[TBL] [Abstract][Full Text] [Related]
30. Eosinophils.
Radonjic-Hösli S; Simon HU
Chem Immunol Allergy; 2014; 100():193-204. PubMed ID: 24925399
[TBL] [Abstract][Full Text] [Related]
31. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
Legrand F; Tomasevic N; Simakova O; Lee CC; Wang Z; Raffeld M; Makiya MA; Palath V; Leung J; Baer M; Yarranton G; Maric I; Bebbington C; Klion AD
J Allergy Clin Immunol; 2014 May; 133(5):1439-47, 1447.e1-8. PubMed ID: 24530099
[TBL] [Abstract][Full Text] [Related]
32. Siglec-7 on peripheral blood eosinophils: Surface expression and function.
Legrand F; Landolina N; Zaffran I; Emeh RO; Chen E; Klion AD; Levi-Schaffer F
Allergy; 2019 Jul; 74(7):1257-1265. PubMed ID: 30690753
[TBL] [Abstract][Full Text] [Related]
33. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
34. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
35. Eosinophils in the Field of Nasal Polyposis: Towards a Better Understanding of Biologic Therapies.
Vanderhaegen T; Gengler I; Dendooven A; Chenivesse C; Lefèvre G; Mortuaire G
Clin Rev Allergy Immunol; 2022 Feb; 62(1):90-102. PubMed ID: 33496939
[TBL] [Abstract][Full Text] [Related]
36. CCL4 Regulates Eosinophil Activation in Eosinophilic Airway Inflammation.
Chu HH; Kobayashi Y; Bui DV; Yun Y; Nguyen LM; Mitani A; Suzuki K; Asako M; Kanda A; Iwai H
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555793
[TBL] [Abstract][Full Text] [Related]
37. Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis.
Di Lorenzo G; Drago A; Esposito Pellitteri M; Candore G; Colombo A; Gervasi F; Pacor ML; Purello D'Ambrosio F; Caruso C
Int Arch Allergy Immunol; 2001 Jun; 125(2):164-75. PubMed ID: 11435734
[TBL] [Abstract][Full Text] [Related]
38. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
39. Roles and regulation of gastrointestinal eosinophils in immunity and disease.
Jung Y; Rothenberg ME
J Immunol; 2014 Aug; 193(3):999-1005. PubMed ID: 25049430
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-5 and eosinophils as therapeutic targets for asthma.
Foster PS; Hogan SP; Yang M; Mattes J; Young IG; Matthaei KI; Kumar RK; Mahalingam S; Webb DC
Trends Mol Med; 2002 Apr; 8(4):162-7. PubMed ID: 11927273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
